Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: A preliminary evaluation

Parasites and Vectors

Volumn 4, Issue 1, 2011, Pages

  Carrión, Javier ^a   Folgueira, Cristina ^a   Soto, Manuel ^a   Fresno, Manuel ^a   Requena, Jose M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G ANTIBODY; LEISHMANIA VACCINE; LIVE VACCINE; NITRIC OXIDE; IMMUNOGLOBULIN G; PROTOZOON ANTIBODY; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DNA MODIFICATION; DRUG SAFETY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; LEISHMANIA INFANTUM; MALE; MOUSE; NONHUMAN; SCID MOUSE; SYRIAN HAMSTER; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENE DELETION; GENETICS; HAMSTER; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA MAJOR; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOGENICITY; RODENT DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; TH1 CELL; VACCINATION;

ANIMALIA; CANIS FAMILIARIS; CRICETINAE; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; MESOCRICETUS AURATUS; MUS;

ANIMALS; ANTIBODIES, PROTOZOAN; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; HSP70 HEAT-SHOCK PROTEINS; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; MICE, SCID; NITRIC OXIDE; RODENT DISEASES; TH1 CELLS; VACCINATION; VACCINES, ATTENUATED; VIRULENCE FACTORS;

EID: 79960690902     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/1756-3305-4-150     Document Type: Article

References (48)

1. Advances in leishmaniasis. Murray HW, Berman JD, Davies CR, Saravia NG, Lancet 2005 366 9496 1561 1577 10.1016/S0140-6736(05)67629-5 16257344 (Pubitemid 41540115)
2. Clinical spectrum of Leishmaniasis. Pearson RD, de Queiroz Sousa A, Clin Infect Dis 1996 22 1 1 13 10.1093/clinids/22.1.1 8824958 (Pubitemid 26022004)
3. Leishmaniasis: current situation and new perspectives. Desjeux P, Comp Immunol Microbiol Infect Dis 2004 27 5 305 318 10.1016/j.cimid.2004.03.004 15225981 (Pubitemid 38842803)
4. Leishmania/HIV co-infections in the second decade. Cruz I, Nieto J, Moreno J, Cãavate C, Desjeux P, Alvar J, Indian J Med Res 2006 123 3 357 388 16778317 (Pubitemid 43905576)
5. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M, Nat Rev Microbiol 2007 5 11 873 882 17938629 (Pubitemid 47578388)
6. Present status of antileishmanial vaccines. Ghosh M, Bandyopadhyay S, Mol Cell Biochem 2003 253 1-2 199 205 14619970 (Pubitemid 37321726)
7. Recent advances in vaccines for leishmaniasis. Requena JM, Iborra S, Carrion J, Alonso C, Soto M, Expert Opin Biol Ther 2004 4 9 1505 1517 10.1517/14712598.4.9.1505 15335317 (Pubitemid 39222982)
8. Leishmaniasis vaccine candidates for development: a global overview. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F, Indian J Med Res 2006 123 3 423 438 16778321 (Pubitemid 43905580)
9. Leishmania vaccines: progress and problems. Kedzierski L, Zhu Y, Handman E, Parasitology 2006 133 Suppl 87 112 17274851
10. Vaccines for leishmaniasis in the fore coming 25 years. Palatnik-de-Sousa CB, Vaccine 2008 26 14 1709 1724 10.1016/j.vaccine.2008.01.023 18295939
11. Leishmania vaccines: from leishmanization to the era of DNA technology. Dunning N, BioscienceHorizons 2009 2 1 73 82
12. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Okwor I, Uzonna J, Immunol Res 2008 41 2 123 136 10.1007/s12026-008-8016-2 18389179
13. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, Modabber F, Vaccine 2005 23 28 3642 3648 10.1016/j.vaccine.2005.02.015 15882524 (Pubitemid 40692409)
14. First generation leishmaniasis vaccines: a review of field efficacy trials. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, Sharifi I, Khalil EA, Velez-Bernal ID, Antunes CMF, et al. Vaccine 2008 26 52 6759 6767 10.1016/j.vaccine.2008.09.085 18950671
15. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis. Okwor I, Liu D, Uzonna J, Vaccine 2009 27 19 2554 2562 10.1016/j.vaccine.2009. 01.133 19428861
16. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, Nature 2002 420 6915 502 507 10.1038/nature01152 12466842 (Pubitemid 35477041)
17. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Selvapandiyan A, Duncan R, Debrabant A, Lee N, Sreenivas G, Salotra P, Nakhasi HL, Indian J Med Res 2006 123 3 455 466 16778323 (Pubitemid 43905582)
18. Live attenuated Leishmania vaccines: a potential strategic alternative. Silvestre R, Cordeiro-da-Silva A, Ouaissi A, Arch Immunol Ther Exp (Warsz) 2008 56 2 123 126 10.1007/s00005-008-0010-9
19. Protozomics: trypanosomatid parasite genetics comes of age. Beverley SM, Nat Rev Genet 2003 4 1 11 19 12509749 (Pubitemid 36043211)
20. Development of a safe live Leishmania vaccine line by gene replacement. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM, Proc Natl Acad Sci USA 1995 92 22 10267 10271 10.1073/pnas.92.22.10267 7479765
21. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. Streit JA, Recker TJ, Filho FG, Beverley SM, Wilson ME, J Immunol 2001 166 3 1921 1929 11160240 (Pubitemid 32114679)
22. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C, Fillion I, Singh AK, Olivier M, Ouellette M, Infect Immun 2002 70 1 62 68 10.1128/IAI.70.1.62-68.2002 11748164 (Pubitemid 34028599)
23. Persistence without pathology in phosphoglycan-deficient Leishmania major. Spath GF, Lye L-F, Segawa H, Sacks DL, Turco SJ, Beverley SM, Science 2003 301 5637 1241 1243 10.1126/science.1087499 12947201 (Pubitemid 37052214)
24. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. Uzonna JE, Spath GF, Beverley SM, Scott P, J Immunol 2004 172 6 3793 3797 15004184 (Pubitemid 38337964)
25. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM, Infect Immun 2004 72 6 3622 3627 10.1128/IAI.72.6.3622-3627.2004 15155672 (Pubitemid 38697791)
26. Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. Ilg T, Demar M, Harbecke D, J Biol Chem 2001 276 7 4988 4997 10.1074/jbc.M008030200 11071892
27. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. Alexander J, Coombs GH, Mottram JC, J Immunol 1998 161 12 6794 6801 9862710 (Pubitemid 28562223)
28. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Saravia NG, Escorcia B, Osorio Y, Valderrama L, Brooks D, Arteaga L, Coombs G, Mottram J, Travi BL, Vaccine 2006 24 19 4247 4259 10.1016/j.vaccine.2005.05.045 16216395
29. Characterisation of a Leishmania mexicana knockout lacking guanosine diphosphate-mannose pyrophosphorylase. Stewart J, Curtis J, Spurck TP, Ilg T, Garami A, Baldwin T, Courret N, McFadden GI, Davis A, Handman E, Int J Parasitol 2005 35 8 861 873 10.1016/j.ijpara.2005.03.008 15936761 (Pubitemid 40905203)
30. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D, Ouaissi A, J Immunol 2007 179 5 3161 3170 17709531
31. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL, J Immunol 2009 183 3 1813 1820 10.4049/jimmunol.0900276 19592661
32. The translational efficiencies of the two Leishmania infantum HSP70 mRNAs, differing in their 3'-untranslated regions, are affected by shifts in the temperature of growth through different mechanisms. Folgueira C, Quijada L, Soto M, Abanades DR, Alonso C, Requena JM, J Biol Chem 2005 280 42 35172 35183 10.1074/jbc.M505559200 16105831 (Pubitemid 41532704)
33. Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Requena JM, Soto M, Doria MD, Alonso C, Vet Immunol Immunopathol 2000 76 3-4 269 281 10.1016/S0165-2427(00)00221-X 11044559
34. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Buffet PA, Sulahian A, Garin YJ, Nassar N, Derouin F, Antimicrob Agents Chemother 1995 39 9 2167 2168 8540741
35. Effects of the disruption of the HSP70-II gene on the growth, morphology, and virulence of Leishmania infantum promastigotes. Folgueira C, Carrion J, Moreno J, Saugar JM, Cãavate C, Requena JM, Int Microbiol 2008 11 2 81 89 18645958
36. Immunopathogenesis of infection with the visceralizing Leishmania species. Wilson ME, Jeronimo SMB, Pearson RD, Microb Pathog 2005 38 4 147 160 10.1016/j.micpath.2004.11.002 15797810 (Pubitemid 40417730)
37. Leishmaniasis: current status of vaccine development. Handman E, Clin Microbiol Rev 2001 14 2 229 243 10.1128/CMR.14.2.229-243.2001 11292637 (Pubitemid 32294669)
38. The host response to Leishmania infection. Solbach W, Laskay T, Adv Immunol 2000 74 275 317 10605608
39. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. Miles SA, Conrad SM, Alves RG, Jeronimo SMB, Mosser DM, J Exp Med 2005 201 5 747 754 10.1084/jem.20041470 15753208 (Pubitemid 40395120)
40. LeishVet guidelines for the practical management of canine leishmaniosis. Solano-Gallego L, Miro G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, Bourdeau P, Oliva G, Baneth G, Parasit Vectors 2011 4 1 86. 10.1186/1756-3305-4-86 21599936
41. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA, Proc Natl Acad Sci USA 1996 93 10 5141 5145 10.1073/pnas.93.10.5141 8643542 (Pubitemid 26162885)
42. LmxPK4, a mitogen-activated protein kinase kinase homologue of Leishmania mexicana with a potential role in parasite differentiation. Kuhn D, Wiese M, Mol Microbiol 2005 56 5 1169 1182 10.1111/j.1365-2958.2005.04614.x 15882412 (Pubitemid 40756002)
43. Spontaneous recovery of pathogenicity by Leishmania major hsp100-/- alters the immune response in mice. Reiling L, Jacobs T, Kroemer M, Gaworski I, Graefe S, Clos J, Infect Immun 2006 74 11 6027 6036 10.1128/IAI.00773-05 17057085 (Pubitemid 44657380)
44. An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice. Engwerda CR, Smelt SC, Kaye PM, Exp Parasitol 1996 84 2 195 202 10.1006/expr.1996.0105 8932769 (Pubitemid 26399786)
45. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. Leclercq V, Lebastard M, Belkaid Y, Louis J, Milon G, J Immunol 1996 157 10 4537 4545 8906832 (Pubitemid 126449375)
46. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. Melby PC, Chandrasekar B, Zhao W, Coe JE, J Immunol 2001 166 3 1912 1920 11160239 (Pubitemid 32114678)
47. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Gifawesen C, Farrell JP, Infect Immun 1989 57 10 3091 3096 2528507 (Pubitemid 19240078)
48. Canine leishmaniosis in South America. Dantas-Torres F, Parasit Vectors 2009 2 Suppl 1 1 10.1186/1756-3305-2-S1-S1 19778462